Publication | Open Access

Switching to nilotinib versus imatinib dose escalation in patients with chronic myeloid leukaemia in chronic phase with suboptimal response to imatinib (LASOR): a randomised, open-label trial

Chronic PhaseOpen-label TrialHematological MalignancyMedicineMixed-phenotype Acute LeukemiaHematologyClinical TrialsMyeloid NeoplasiaSuboptimal ResponsePharmacotherapyOncologyRadiation OncologyCancer ResearchHealth Sciences